Skip to main content

Market Overview

Biotech Is Getting A Big Boost Following Clinton's Loss

Share:
Biotech Is Getting A Big Boost Following Clinton's Loss

Investors in biotech stocks were getting a little weary leading up to the Presidential elections. However, with the results in favor of Donald Trump, biotech stocks are trading higher.

Some of the stocks are gaining significantly in Wednesday's pre-market session. Clinton was not happy with drug pricing by pharmaceutical firms, and many feared of the price cuts and regulations her presidency might bring to the table.

The following stocks gained in the pre-market trading on Wednesday:

  • SPDR S&P Biotech (ETF) (NYSE: XBI) trading up 4.8 percent to $60.60
  • iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) added 4.33 percent to $272.96.
  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX), which tanked 21.69 percent on Tuesday, gained 1.13 percent to $15.15.
  • Mylan NV (NASDAQ: MYL) jumped 5.85 percent to $39.28.
  • Pfizer Inc. (NYSE: PFE) advanced 7.33 percent to $32.25.
  • Eli Lilly and Co (NYSE: LLY) gained 3.01 percent to $76.25.
  • Amgen, Inc. (NASDAQ: AMGN) was up 2.82 percent to $142.35.
  • Gilead Sciences, Inc. (NASDAQ: GILD) added 1.94 percent to $75.50.
  • Merck & Co., Inc. (NYSE: MRK) gained 2.88 percent to $62.25.
  • Novartis AG (ADR) (NYSE: NVS) advanced 2.41 percent to $73.00.
 

Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech News Pre-Market Outlook Movers General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com